Related Experiment Video
Updated: Jul 22, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
Published on: November 10, 2008
Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline
M Moonis1, J M Swearer, M P E Dayaw
1Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655, USA.
Abstract:
CSF amyloid beta-peptide 42 (Abeta42) levels in presymptomatic subjects with pathogenic mutations in the PS1 gene are significantly lower than in an age-matched control group. Consequently, in these subjects, there is a window of opportunity estimated as at least 4 to 12 years to evaluate the ability of any putative prophylactic therapy to decrease, arrest, or reverse abnormalities in Abeta42 metabolism many years before clinical symptoms of Alzheimer disease are otherwise likely to occur.
More Related Videos
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction